Xign

Xigen was a Swiss biotechnology company focused on the discovery and development of innovative therapeutic peptides for the treatment of inflammatory and neurodegenerative diseases. The company's primary focus was on the development of c-Jun N-terminal kinase (JNK) inhibitors, which play a crucial role in cell death and inflammation pathways. Its lead candidate, brimapitide (XG-102), was investigated for various indications including hearing loss and ocular inflammation. In 2020, Xigen's key assets and JNK inhibitor programs were acquired by Auris Medical (now Altamira Therapeutics), which continues to develop the technology for inner ear and ocular disorders.